China Competitors Gain Shares From GSK As Anti-Graft Probe Continues
This article was originally published in PharmAsia News
Executive Summary
Domestic competitors are the main gainers from reported sales declines of some GlaxoSmithKline products in China following anti-graft investigations that began in July, according to a report.